Copyright
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Heart disease in Friedreich’s ataxia
Emily Hanson, Mark Sheldon, Brenda Pacheco, Mohammed Alkubeysi, Veena Raizada, Department of Internal Medicine, Cardiology Section, University of New Mexico, Albuquerque, NM 87106, United States
Author contributions: Hanson E wrote the manuscript; Sheldon M, Pacheco B and Alkubeysi M contributed to the aim of the manuscript and the diagnostic process of the case study used in the manuscript; Raizada V contributed to writing and editing of the manuscript and is the corresponding author.
Conflict-of-interest statement: There are no conflicts of interest to report.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Veena Raizada, MD, Doctor, Professor, Department of Internal Medicine, Cardiology Section, University of New Mexico, 2211 Lomas Blvd NE, Albuquerque, NM 87131, United States. vraizada@salud.unm.edu
Telephone: +1-404-8230602
Received: November 14, 2018
Peer-review started: November 14, 2018
First decision: November 29, 2018
Revised: December 11, 2018
Accepted: January 5, 2019
Article in press: January 6, 2019
Published online: January 26, 2019
Peer-review started: November 14, 2018
First decision: November 29, 2018
Revised: December 11, 2018
Accepted: January 5, 2019
Article in press: January 6, 2019
Published online: January 26, 2019
Core Tip
Core tip: The present review discusses the pathogenesis, clinical manifestations, and spectrum of cardiac disease in Friedreich’s Ataxia, and introduces gene-targeted and pathology-specific therapies, in addition to the screening guidelines that should be used to monitor cardiac disease in this mitochondrial disorder.